About

Mosaiques diagnostics GmbH (MOS), based in Hannover, Germany, is a global leader in clinical proteomics, pioneering capillary electrophoresis–mass spectrometry (CE-MS) since 2002. Its CE-MS platform, validated through >85,000 datasets and 300+ scientific publications, is at TRL 8–9 and FDA-supported.

MOS specializes in urine-based polypeptide biomarkers (DiaPat) for non-invasive, early diagnosis and monitoring of diseases such as cancer (prostate, bladder, bile duct), kidney, liver, and cardiovascular conditions. It has commercialized multiple IVD tests and supports therapy guidance and drug development through biomarker-driven approaches.

With advanced MS infrastructure (e.g., Orbitrap, MicroTOF-Q) and powerful data analysis tools, MOS also manages a high-resolution urinary proteomics database. The company has participated in 44 EU-funded projects, including 12 in oncology, collaborating with over 250 partners across academia, healthcare, and industry.

​

Role in the Project

MOS applies its CE-MS technology to identify and validate urinary peptide biomarkers for cancer detection, focusing on extracellular matrix (ECM)-related features. Urine offers a non-invasive, stable, and accessible sample source, ideal for high-resolution, reproducible proteomic profiling. These biomarker panels aim to capture molecular signatures of tumour-host interactions, invasion, inflammation, and metastasis. MOS contributes its platform, expertise, and large datasets to support the discovery, qualification, and clinical translation of biomarkers to enhance cancer diagnosis and treatment outcomes.

​

​

MOS team:

Prof. Harald Mischak

Executive Director of Mosaiques Diagnostics GmbH, Chief Scientifc Officer of Mosaiques Diagnostics & Therapeutics AG

 

Dr. Maria Frantzi

Senior scientists